Loss- and gain-of-function PCSK9 variants: Cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation

Journal of Biological Chemistry

Volumn 287, Issue 40, 2012, Pages 33745-33755

  Benjannet, Suzanne ^a   Hamelin, Josée ^a   Chrétien, Michel ^b,c   Seidah, Nabil G ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCATALYTIC; CLEAVAGE SITES; CLEAVAGE SPECIFICITY; CONTROL PROPERTIES; DEGRADATION ACTIVITY; DOMINANT NEGATIVE; ENDOPLASMIC RETICULUM; ENDOSOMES; HYPERCHOLESTEROLEMIA; LOW DENSITY LIPOPROTEIN RECEPTORS; NATIVE PROTEINS; SMALL MOLECULE INHIBITOR;

PROTEINS;

CELL MEMBRANES;

ALANINE; ASPARAGINE; CYSTEINE; ENZYME PRECURSOR; GLUTAMINE; LOW DENSITY LIPOPROTEIN RECEPTOR; METHIONINE; PROPROTEIN CONVERTASE 9; SERINE; SERINE PROTEINASE; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME DEGRADATION; ENZYME SPECIFICITY; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MUTAGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT;

ALTERNATIVE SPLICING; CATALYSIS; CHOLESTEROL; CHOLESTEROL, LDL; ENZYME PRECURSORS; FLOW CYTOMETRY; GENES, DOMINANT; HEK293 CELLS; HUMANS; HYPERCHOLESTEROLEMIA; MODELS, BIOLOGICAL; MUTATION; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 84866924889     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.399725     Document Type: Article

References (53)

1. Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., and Prat, A. (2008) The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40, 1111-1125
2. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383
3. Chrétien, M. (2012) My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochem. Cell Biol., in press
4. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933 (Pubitemid 36183932)
5. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (Pubitemid 36666925)
6. Maxwell, K. N., and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U.S.A. 101, 7100-7105 (Pubitemid 38596449)
7. Maxwell, K. N., Fisher, E. A., and Breslow, J. L. (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. U.S.A. 102, 2069-2074 (Pubitemid 40262013)
8. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M., Prat, A., and Seidah, N. G. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875 (Pubitemid 39625767)
9. Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732 (Pubitemid 46785153)
10. Naureckiene, S., Ma, L., Sreekumar, K., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., Kennedy, J. D., DiStefano, P. S., Wood, A., and Bingham, B. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 420, 55-67 (Pubitemid 37393374)
11. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman- Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419 (Pubitemid 46685885)
12. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282, 20799-20803 (Pubitemid 47099894)
13. Li, J., Tumanut, C., Gavigan, J. A., Huang, W. J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., Liau, G., Yowe, D., and Harris, J. L. (2007) Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406, 203-207 (Pubitemid 47310950)
14. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372
15. Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., and Chrétien, M. (2011) Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin. Chem. 57, 1415-1423
16. Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., and Swergold, G. D. (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118
17. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825 (Pubitemid 351439423)
18. Surdo, P. L., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., and Carfí, A. (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12, 1300-1305
19. Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., and Shattuck, D. M. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114, 349-353 (Pubitemid 38324948)
20. Fisher, T. S., Lo Surdo, P., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., Tarachandani, A., De Francesco, R., Wright, S. D., Sparrow, C. P., Carfi, A., and Sitlani, A. (2007) PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J. Biol. Chem. 282, 20502-20512 (Pubitemid 47100016)
21. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Investig. 116, 2995-3005 (Pubitemid 44684484)
22. Fasano, T., Sun, X. M., Patel, D. D., and Soutar, A. K. (2009) Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 203, 166-171
23. Bourbon, M., Alves, A. C., Medeiros, A. M., Silva, S., and Soutar, A. K. (2008) Familial hypercholesterolaemia in Portugal. Atherosclerosis 196, 633-642
24. Benjannet, S., Elagoz, A., Wickham, L., Mamarbachi, M., Munzer, J. S., Basak, A., Lazure, C., Cromlish, J. A., Sisodia, S., Checler, F., Chrétien, M., and Seidah, N. G. (2001) Post-translational processing of β-secretase (β- amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid- β production. J. Biol. Chem. 276, 10879-10887 (Pubitemid 38089265)
25. Lin, J. H., Li, H., Yasumura, D., Cohen, H. R., Zhang, C., Panning, B., Shokat, K. M., Lavail, M. M., and Walter, P. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science 318, 944-949 (Pubitemid 350098984)
26. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., and Mori, K. (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881-891 (Pubitemid 34084979)
27. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N. G. (2006) The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281, 30561-30572 (Pubitemid 44582112)
28. Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., and Davignon, J. (2010) A new method for measurement of total plasma PCSK9: clinical applications. J. Lipid Res. 51, 140-149
29. Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., and Prat, A. (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286, 4257-4263
30. Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., and Hobbs, H. H. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410-422 (Pubitemid 43291224)
31. Rousselet, E., Benjannet, S., Hamelin, J., Canuel, M., and Seidah, N. G. (2011) The proprotein convertase PC7: unique zymogen activation and trafficking pathways. J. Biol. Chem. 286, 2728-2738
32. Benjannet, S., Saavedra, Y. G., Hamelin, J., Asselin, M. C., Essalmani, R., Pasquato, A., Lemaire, P., Duke, G., Miao, B., Duclos, F., Parker, R., Mayer, G., and Seidah, N. G. (2010) Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J. Biol. Chem. 285, 40965-40978
33. Zhong, M., Munzer, J. S., Basak, A., Benjannet, S., Mowla, S. J., Decroly, E., Chrétien, M., and Seidah, N. G. (1999) The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J. Biol. Chem. 274, 33913-33920 (Pubitemid 129511719)
34. Nour, N., Basak, A., Chrétien, M., and Seidah, N. G. (2003) Structurefunction analysis of the prosegment of the proprotein convertase PC5A. J. Biol. Chem. 278, 2886-2895 (Pubitemid 36801193)
35. Pullikotil, P., Vincent, M., Nichol, S. T., and Seidah, N. G. (2004) Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein. J. Biol. Chem. 279, 17338-17347 (Pubitemid 38560494)
36. Siezen, R. J., and Leunissen, J. A. (1997) Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci. 6, 501-523 (Pubitemid 27120048)
37. Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165
38. Gutiérrez-Cirlos, C., Ordóñez-Sánchez, M. L., Tusié-Luna, M. T., Patterson, B. W., Schonfeld, G., and Aguilar-Salinas, C. A. (2011) Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and nonalcoholic fatty liver disease. Ann. Hepatol. 10, 155-164
39. Shinde, U., and Thomas, G. (2011) Insights from bacterial subtilases into the mechanisms of intramolecular chaperone-mediated activation of furin. Methods Mol. Biol. 768, 59-106
40. Pandit, S., Wisniewski, D., Santoro, J. C., Ha, S., Ramakrishnan, V., Cubbon, R. M., Cummings, R. T., Wright, S. D., Sparrow, C. P., Sitlani, A., and Fisher, T. S. (2008) Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J. Lipid Res. 49, 1333-1343
41. Seidah, N. G. (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets 13, 19-28
42. Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2009) PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50, (suppl.) S172-S177
43. Akram, O. N., Bernier, A., Petrides, F., Wong, G., and Lambert, G. (2010) Beyond LDL cholesterol, a new role for PCSK9. Arterioscler. Thromb. Vasc. Biol. 30, 1279-1281
44. Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, S., Njimoluh, L., Wood, D. D., Hammond, H. A., Wisniewski, D., Volpari, C., Noto, A., Lo Surdo, P., Hubbard, B., Carfí, A., and Sitlani, A. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285, 12882-12891
45. Zhang, Y., Zhou, L., Beltran, M. K., Li, W., Moran, P., Wang, J., Quan, C., Tom, J., Kolumam, G., Elliott, J. M., Skelton, N., Peterson, A., and Kirchhofer, D. (2012) Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain. J. Mol. Biol., in press
46. Mayer, G., Poirier, S., and Seidah, N. G. (2008) Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283, 31791-31801
47. Seidah N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat A, Wassef, H., Davignon, J., Hajjar, K. A., and Mayer, G. (2012) Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One 7, e41865
48. Geoghegan, K. F., Hoth, L. R., Varghese, A. H., Lin, W., Boyd, J. G., and Griffor, M. C. (2009) Binding to low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme. Biochemistry 48, 2941-2949
49. Cariou, B., Ouguerram, K., Zaïr, Y., Guerois, R., Langhi, C., Kourimate, S., Benoit, I., Le May, C., Gayet, C., Belabbas, K., Dufernez, F., Chétiveaux, M., Tarugi, P., Krempf, M., Benlian, P., and Costet, P. (2009) PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 29, 2191-2197
50. Abifadel, M., Rabès, J. P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., and Boileau, C. (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30, 520-529
51. Abifadel, M., Guerin, M., Benjannet, S., Rabès, J. P., Le Goff, W., Julia, Z., Hamelin, J., Carreau, V., Varret, M., Bruckert, E., Tosolini, L., Meilhac, O., Couvert, P., Bonnefont-Rousselot, D., Chapman, J., Carrié, A., Michel, J. B., Prat, A., Seidah, N. G., and Boileau, C. (2012) Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 223, 394-400
52. Sun, X. M., Eden, E. R., Tosi, I., Neuwirth, C. K., Wile, D., Naoumova, R. P., and Soutar, A. K. (2005) Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum. Mol. Genet. 14, 1161-1169 (Pubitemid 40613905)
53. McNutt, M. C., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., and Lagace, T. A. (2009) Antagonism of secreted PCSK9 increases low-density lipoprotein receptor expression in HEPG2 cells. J. Biol. Chem. 284, 10561-10570